Compare RLX Technology Inc (RLX) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
RLX Technology Inc vs Sana Biotechnology Inc — how do they compare? RLX Technology Inc trades at $1.74 (market cap $2.10B), while Sana Biotechnology Inc trades at $2.8 (market cap $836.71M). The key difference: RLX Technology Inc is far larger — about 2.5× Sana Biotechnology Inc's market cap, and RLX Technology Inc pays a 5.81% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold RLX Technology Inc for 35 Days and Sana Biotechnology Inc for 23 Days on average.
| RLX | SANA | |
|---|---|---|
Market Cap | $2.10B | $836.71M |
Volume | 1,079,706 | 4,507,444 |
Sector | Consumer Staples | Health |
52-Week High | $2.57 | $5.92 |
52-Week Low | $1.68 | $2.68 |
Typical Hold Time | 35 Days | 23 Days |
Enterprise Value | $832.26M | $749.96M |
Dividend Yield | 5.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RLX Technology trades at $1.735, up 0.29% with bearish technical signals despite recent 52-week lows. The company shows solid fundamentals with $3.62B revenue, 21.87% net margin, and attractive valuation at P/E 15.46 and P/B 0.91. Recent earnings missed expectations but international expansion drives growth, with 70% revenue now from overseas markets. Cash flow trends improved significantly from -$99M in 2025 to $881M projected for 2026.
RLX presents a value opportunity with discounted valuation and strong international growth, though technical weakness and earnings misses warrant caution. The single analyst coverage maintains Hold rating, reflecting uncertainty amid expansion execution risks and regulatory challenges in the e-vapor industry.
SANA Biotechnology trades at $2.84, up 4.41% today, while showing bearish technical signals with moving averages indicating selling pressure. The company remains pre-revenue with significant losses (-$244.17M net income in 2025) and negative cash flow from operations. Recent investor conference presentations highlight ongoing development of engineered cell therapies, though earnings have missed expectations in two of the last three quarters.
Despite analyst optimism (82% buy ratings), SANA faces substantial execution risk as a clinical-stage biotech with no current revenue and high cash burn. The stock's outlook depends heavily on clinical trial progress and future funding needs, with current valuation at 5.41x book value despite negative profitability metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About RLX Technology Inc
RLX Technology Inc. is a leading e-vapor company in China, focusing on the research, development, and sale of e-vapor products. The company primarily operates under the RELX brand, offering a range of closed-system e-vapor products designed to deliver a high-quality user experience. RLX's business model is centered on product innovation, strong brand building, and a vast distribution network across China.
Read more on RLX →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
